Publicación Artículo científico (article).

Quantitative Proteomics Analysis Reveals That Cyclooxygenase-2 Modulates Mitochondrial Respiratory Chain Complex IV in Cardiomyocytes

Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/283061
Digital.CSIC. Repositorio Institucional del CSIC
  • Alvarez, María Soledad
  • Núñez, Estefanía
  • Fuertes-Agudo, Marina
  • Cucarella, Carme
  • Fernández-Velasco, María
  • Boscá, Lisardo
  • Vázquez, Jesús
  • Rossignol, Rodrigue
  • Martín-Sanz, Paloma
  • Casado, Marta
19 páginas, 9 figuras, 1 tabla, The biochemical mechanisms of cell injury and myocardial cell death after myocardial infarction remain unresolved. Cyclooxygenase 2 (COX-2), a key enzyme in prostanoid synthesis, is expressed in human ischemic myocardium and dilated cardiomyopathy, but it is absent in healthy hearts. To assess the role of COX-2 in cardiovascular physiopathology, we developed transgenic mice that constitutively express functional human COX-2 in cardiomyocytes under the control of the α-myosin heavy chain promoter. These animals had no apparent phenotype but were protected against ischemia-reperfusion injury in isolated hearts, with enhanced functional recovery and diminished cellular necrosis. To further explore the phenotype of this animal model, we carried out a differential proteome analysis of wild-type vs. transgenic cardiomyocytes. The results revealed a tissue-specific proteomic profile dominated by mitochondrial proteins. In particular, an increased expression of respiratory chain complex IV proteins was observed. This correlated with increased catalytic activity, enhanced respiratory capacity, and increased ATP levels in the heart of COX-2 transgenic mice. These data suggest a new link between COX-2 and mitochondria, which might contribute to the protective cardiac effects of COX-2 against ischemia-reperfusion injury., This work was supported by Ministerio de Economia y Competitividad (BIO2012-37926), Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación 10.13039/501100011033 (PID2019- 108977RB-I00; PID2020-113238RB-I00), by Generalitat Valenciana (ACOMP/2011/120), by grant PRB2 (IPT13/0001—ISCIII-SGEFI/FEDER, ProteoRed), Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CB06/04/1069) and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CB/11/00222). M.S.A. was supported by a fellowship from CSIC (Spanish National Research Council) (JAE-predoc). M.F.-A. is a recipient of the FPI fellowship from MINECO (BES-2017-081928)., Peer reviewed
 

DOI: http://hdl.handle.net/10261/283061
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/283061

HANDLE: http://hdl.handle.net/10261/283061
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/283061
 
Ver en: http://hdl.handle.net/10261/283061
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/283061

1106